151. Two-year outcomes of intravitreal ziv-aflibercept
- Author
-
Ahmad M, Mansour, Mohammed, Ashraf, Abdulrazzak, Charbaji, Muhammad H, Younis, Ahmed A, Souka, Avantika, Dogra, Hana A, Mansour, Jay, Chhablani, and Rushil Kumar, And Komal Agrawal
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Visual acuity ,Retinal Vein ,genetic structures ,Fundus Oculi ,Recombinant Fusion Proteins ,Visual Acuity ,Macular oedema ,Treat and extend ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Retinal Diseases ,Optical coherence tomography ,Ophthalmology ,Occlusion ,Humans ,Medicine ,Macula Lutea ,Prospective Studies ,Fluorescein Angiography ,Aged ,Aged, 80 and over ,Dose-Response Relationship, Drug ,medicine.diagnostic_test ,business.industry ,Middle Aged ,Macular degeneration ,medicine.disease ,eye diseases ,Sensory Systems ,Receptors, Vascular Endothelial Growth Factor ,Treatment Outcome ,medicine.anatomical_structure ,Intravitreal Injections ,030221 ophthalmology & optometry ,Female ,sense organs ,Choroid ,medicine.symptom ,business ,Tomography, Optical Coherence ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
AimTo assess the two-year outcome of intravitreal ziv-aflibercept (IVZ) in eyes with macular diseases.MethodsConsecutive subjects with various macular diseases that received six or more of 0.05 mL IVZ (1.25 mg) injections with at least 1 year follow-up were included. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography. Paired comparison was done using Wilcoxon signed-rank test calculator.Results107 eyes of 91 subjects received IVZ and were followed with mean±SD follow-up interval of 1.48±0.44 months following treat and extend or pro-re-nata protocol. The distribution included neovascular macular degeneration (42 eyes), diabetic macular oedema (32 eyes) and macular oedema secondary to retinal vein occlusion (11 eyes). Fifty eyes were naive, while 57 eyes were previously treated. Combining all disease categories, CMT decreased significantly by 133.0±153.0 µm at the 24-month follow-up (PConclusionsIVZ appears safe and efficacious in the therapy of macular diseases through 2 years. more...
- Published
- 2018
- Full Text
- View/download PDF